← Leaderboards
Shivaani Kummar
Oregon Health & Science University
$2,160,891
Attributed
$3,036,091
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,927,626 · 6
By mechanism
P30$4,369,110 · 3
R01$999,096 · 1
R21$378,015 · 1
T32$181,405 · 1
Top collaborators
- Carina Mari Aparici4 shared
- Erik S. Mittra3 shared
- Holden T. Maecker2 shared
- Sanjay V. Malhotra1 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Mindy Roberts$3,617,316
- Jeffrey Wallace Tyner$13,872,769
- Ashley Nicole Anderson$167,838
- Carina Mari Aparici$403,606
- Erik S. Mittra$191,884
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsClinical TrialsCancer PatientTumorDoctor Of MedicinePatient-Focused OutcomesSiteAdvanced Malignant NeoplasmComplexMelanomaTranslational ResearchMonitorProtocols DocumentationPredictive MarkerSafetyImmuneSamplingDesignClinical ResearchEnrollmentImmune SystemImmunotherapyCellsCancer Therapy
Grant awards (14)
OHSU Knight Cancer Institute$2,891,535
P30 · FY2025 · CA · contact PI
Experimental Therapeutics in Cancer Training Program$181,405
T32 · FY2025 · CA · contact PI
[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors$124,109
R01 · FY2025 · CA · contact PI
Clinical Protocol and Data Management$291,253
P30 · FY2024 · CA · contact PI
Protocol Review and Monitoring System$201,272
P30 · FY2024 · CA · contact PI
[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors$1
R01 · FY2024 · CA · contact PI
Clinical Protocol and Data Management$291,253
P30 · FY2023 · CA · contact PI
Protocol Review and Monitoring System$201,272
P30 · FY2023 · CA · contact PI
Clinical Protocol and Data Management$291,253
P30 · FY2022 · CA · contact PI
Protocol Review and Monitoring System$201,272
P30 · FY2022 · CA · contact PI
[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors$451,542
R01 · FY2021 · CA · contact PI
[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors$423,444
R01 · FY2020 · CA · contact PI
PQ3: Age-related immune deviation and cancer outcome$206,190
R21 · FY2017 · CA
PQ3: Age-related immune deviation and cancer outcome$171,825
R21 · FY2016 · CA